<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01809743</url>
  </required_header>
  <id_info>
    <org_study_id>NL42049.060.12</org_study_id>
    <nct_id>NCT01809743</nct_id>
  </id_info>
  <brief_title>Regadenoson and Adenosine</brief_title>
  <official_title>Comparison of Regadenoson (Rapiscan) and Central Intravenous Adenosine for Measurement of Fractional Flow Reserve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lokien van Nunen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catharina Ziekenhuis Eindhoven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to test the accuracy of Regadenoson to induce maximal and steady
      state hyperemia as compared to central venous infusion of adenosine for assessing fractional
      flow reserve. (adenosine is considered to be the gold standard)and to investigate the time
      intervals of maximum hyperemia induced by centrally and peripherally administered
      Regadenoson.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the accuracy of Regadenoson to induce maximal and steady state hyperemia</measure>
    <time_frame>participants will be followed up during hospital stay, an expected average of 1 day</time_frame>
    <description>To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the gold standard).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time intervals of maximum hyperemia</measure>
    <time_frame>participants will be followed up during hospital stay, an expected average of 1 day</time_frame>
    <description>To investigate the time intervals of maximum hyperemia induced by centrally and peripherally administered Regadenoson.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Regadenoson central - peripheral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First bolus regadenoson administered central, second bolus administered peripheral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regadenoson peripheral - central</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First bolus regadenoson administered peripheral, second bolus administered central</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regadenoson central - central</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First bolus regadenoson administered central, second bolus administered central</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regadenoson peripheral - peripheral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First bolus regadenoson administered peripheral, second bolus administered peripheral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regadenoson central -central</intervention_name>
    <description>To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).</description>
    <arm_group_label>Regadenoson central - central</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regadenoson peripheral - peripheral</intervention_name>
    <description>To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).</description>
    <arm_group_label>Regadenoson peripheral - peripheral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regadenoson central - peripheral</intervention_name>
    <description>To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).</description>
    <arm_group_label>Regadenoson central - peripheral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regadenoson peripheral - central</intervention_name>
    <description>To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).</description>
    <arm_group_label>Regadenoson peripheral - central</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosine</intervention_name>
    <description>Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.</description>
    <arm_group_label>Regadenoson central - peripheral</arm_group_label>
    <arm_group_label>Regadenoson peripheral - central</arm_group_label>
    <arm_group_label>Regadenoson central - central</arm_group_label>
    <arm_group_label>Regadenoson peripheral - peripheral</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-80 years

          -  Scheduled for invasive measurement of FFR for diagnostic and interventional purposes
             in proximal or mid segments of a coronary artery

        Exclusion Criteria:

          -  Severe aortic valve stenosis

          -  History of severe COPD

          -  Syncope or bradycardia (less than 50 beats/min)

          -  Known conduction disturbances (2nd-3rd degree heart-block, sick sinus without
             pacemaker or long QT-syndrome)

          -  Severe hypotension (RR &lt;90 mmHg)

          -  Patients in whom no access to the coronary circulation can be obtained by the femoral
             artery or in whom femoral access was problematic

          -  Coronary anatomy not suitable for FFR measurement (extremely tortuous or calcified
             coronary vessels)

          -  Previous coronary bypass surgery

          -  Recent ST elevation myocardial infarction (&lt;5 days)

          -  Recent non-ST elevation myocardial infarction (&lt;5 days) if the peak CK is &gt;1000 IU

          -  Inability to provide informed consent

          -  Pregnancy

          -  Use of methylxanthines (in the last 12 hours)

          -  Use of Dipyridamol (in the last 48 hours)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nico H.J. Pijls, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina Ziekenhuis Eindhoven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lokien X van Nunen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Catharina Ziekenhuis Eindhoven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catharina Hospital</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2012</study_first_submitted>
  <study_first_submitted_qc>March 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2013</study_first_posted>
  <last_update_submitted>November 11, 2013</last_update_submitted>
  <last_update_submitted_qc>November 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Catharina Ziekenhuis Eindhoven</investigator_affiliation>
    <investigator_full_name>Lokien van Nunen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Coronary artery disease</keyword>
  <keyword>Regadenoson</keyword>
  <keyword>Adenosine</keyword>
  <keyword>Maximal hyperemia</keyword>
  <keyword>Fractional flow reserve</keyword>
  <keyword>FFR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
    <mesh_term>Regadenoson</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

